rss
Br J Ophthalmol 2009;93:47-51 doi:10.1136/bjo.2008.143461
  • Original Article
    • Clinical science

Intravitreal bevacizumab (Avastin) treatment of choroidal neovascularisation in patients with angioid streaks

  1. T W Wiegand1,2,
  2. A H Rogers1,
  3. F McCabe1,3,
  4. E Reichel1,
  5. J S Duker1
  1. 1
    New England Eye Center, Tufts Medical Center, Boston, Massachusetts, USA
  2. 2
    Ophthalmic Consultants of Boston, Boston, Massachusetts, USA
  3. 3
    Vitreo-Retinal Associates, Worcester, Massachusetts, USA
  1. Dr A H Rogers, 800 Washington Street, Box 450, Boston, MA 02111, USA; arogers1{at}tuftsmedicalcenter.org
  • Accepted 27 September 2008
  • Published Online First 29 October 2008

Abstract

Objective: To evaluate the safety and efficacy of intravitreal bevacizumab (Avastin) as treatment for choroidal neovascularisation (CNV) associated with angioid streaks

Methods: A non-randomised, interventional case series conducted on eyes with subfoveal CNV associated with angioid streaks. Intravitreal bevacizumab (1.25 mg in 0.05 ml) was injected into nine eyes of six patients between August 2005 and December 2007. Treatment efficacy was assessed based on pre- and post-treatment visual acuity and optical coherence tomography (OCT).

Results: With a mean follow-up of 19 months (range 10 to 28 months), the best corrected visual acuity improved by three or more lines in four eyes (44.4%), remained within two lines of baseline in four eyes (44.4%) and decreased by three or more lines in one eye (11.1%). Central foveal thickness (CFT) measured by OCT decreased an average of 67.7 μm (range +11 to −175 μm) with an average improvement in standardised change in macular thickening of 46.6% (range −12% to +84.5%). No injection-related complications or drug-related side effects were observed.

Conclusions: Intravitreal bevazicumab for the treatment of subfoveal CNV secondary to angioid streaks mildly reduced central foveal thickness with a trend toward stabilisation of visual acuity. Additional follow-up and a larger patient cohort are needed to evaluate the long-term effects of this treatment.

Footnotes

  • Competing interests: None.

  • Funding: This work was supported in part by an RPB Challenge grant to the New England Eye Center/Department of Ophthalmology, Tufts University School of Medicine and in part by a departmental grant from Massachusetts Lions.

  • Ethics approval: Ethics approval was provided by the institutional review board of Tufts Medical Center, Boston, Massachusetts, USA.

  • Patient consent: Obtained.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All Versions of this Article:
    1. bjo.2008.143461v1
    2. 93/1/47 most recent

Services

  1. Email this link to a friend
  2. Alert me when this article is cited
  3. Alert me if a correction is posted
  4. Alert me when eletters are published
  5. Article Usage Statistics
  6. Similar articles in this journal
  7. Similar articles in Web of Science
  8. Similar articles in PubMed
  9. Add article to my folders
  10. Download to citation manager
  11. Request permissions

Responses

  1. Submit a response
  2. No responses published

Social bookmarking

Register for free content


Free sample
 This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
View free sample issue >>

Free archive
The full back archive is now available for BJO. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.